- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
Patent holdings for IPC class A61K 40/11
Total number of patents in this class: 1574
10-year publication summary
|
0
|
0
|
2
|
6
|
21
|
71
|
89
|
42
|
38
|
791
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Trustees of the University of Pennsylvania | 4376 |
39 |
| The Regents of the University of California | 20268 |
36 |
| Iovance Biotherapeutics, Inc. | 346 |
27 |
| Memorial Sloan-Kettering Cancer Center | 1979 |
26 |
| Kite Pharma, Inc. | 412 |
24 |
| Juno Therapeutics, Inc. | 451 |
22 |
| Fred Hutchinson Cancer Center | 463 |
21 |
| The Board of Trustees of the Leland Stanford Junior University | 6526 |
20 |
| City of Hope | 1009 |
19 |
| Board of Regents, The University of Texas System | 5927 |
18 |
| The General Hospital Corporation | 4797 |
18 |
| Immatics Biotechnologies GmbH | 1158 |
17 |
| Dana-Farber Cancer Institute, Inc. | 2621 |
16 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 984 |
16 |
| Autolus Limited | 260 |
15 |
| Janssen Biotech, Inc. | 1581 |
15 |
| Allogene Therapeutics, Inc. | 153 |
15 |
| Novartis AG | 10626 |
13 |
| Memorial Hospital for Cancer and Allied Diseases | 319 |
13 |
| Sloan-Kettering Institute for Cancer Research | 541 |
12 |
| Other owners | 1172 |